Surgical Apgar Score (SAS)
Intraoperative 3-variable score predicting major postoperative complications and death within 30 days.
Score interpretation
SAS 9–10 — about 4–5 % major complications or death within 30 days (Gawande 2007; Regenbogen 2009)
→ Routine post-operative monitoring; standard ward care appropriate; ERAS (Enhanced Recovery After Surgery) pathway if applicable; standard analgesia; reassess if clinical deterioration
SAS 7–8 — intermediate risk, lower than scores ≤ 6
→ Ward-based post-operative monitoring; ensure adequate fluid resuscitation; observe for complications (haemorrhage, infection, AKI, respiratory); escalate if NEWS2 rising; standard enhanced recovery pathway; GP follow-up arranged
SAS 5–6 — intermediate risk, higher than scores ≥ 7
→ Level 1 or HDU monitoring recommended postoperatively; fluid balance charting; regular NEWS2 assessments; early senior review if deteriorating; ensure IV access maintained; thromboprophylaxis; nutritional support; surgical review at 24 and 48 hours
SAS 0–4 — about 56–59 % major complications or death within 30 days (Gawande 2007; Regenbogen 2009)
→ Consider HDU/ICU-level monitoring; optimise haemodynamics and fluid balance; senior surgical, anaesthetic and critical care review; low threshold to investigate complications
Interpretation bands for the Surgical Apgar. Apply clinical judgement and local guidance.
References
- Gawande AA, et al. An Apgar score for surgery. J Am Coll Surg. 2007;204(2):201–208.
- Regenbogen SE, et al. Utility of the surgical Apgar score: validation in 4119 patients. Arch Surg. 2009;144(1):30–36.
Related
Curated clinical cross-links plus same-class fallbacks.
- Tranexamic Acid (ICU/Trauma/Surgical) · Antifibrinolytic
- Cefuroxime · Second-Generation Cephalosporin — Respiratory / Surgical Prophylaxis
- Cefazolin · First-Generation Cephalosporin (Surgical Prophylaxis)
- Palivizumab · RSV Prophylaxis — Monthly Monoclonal Antibody (High-Risk Infants)
- Ziprasidone · Atypical Antipsychotic — D2/5-HT2A Antagonist (Low Metabolic Risk)
- Atorvastatin (CKD Cardiovascular Risk) · Cardiovascular Risk in CKD
- Major Trauma — Primary Survey (ATLS) · ATLS 10th Edition; JRCALC; NICE NG39
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Burns — TBSA Estimation & Fluid Resuscitation · British Burn Association; EMSB; RCEM 2024
- Lower Gastrointestinal Bleed · NICE; BSG; ACPGBI — Commissioning Guide
- Acute Pancreatitis · NICE; IAP/APA; ACPGBI — CG104
- Hypertrophic Pyloric Stenosis · BAPS / RCPCH
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.